Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study.
Ruopeng SuTingxuan HuangLiangyou GuYige BaoZhihong LiuPinghong DaoLin YaoXiaoyi HuGuanghou FuJitao WuThibault TricardGuangyu WuMinfeng ChenChancan LiZhiyang HuangBing ZhengYonghui ChenWei XueGang GuoPei DongJiwei HuangJin ZhangPublished in: Cancer medicine (2024)
Everolimus was effective and well-tolerated in neoadjuvant treatment for renal AML, especially in TSC patients. This neoadjuvant combination strategy of everolimus and PN could effectively controls recurrence and preserves renal function.
Keyphrases
- rectal cancer
- locally advanced
- lymph node
- end stage renal disease
- ejection fraction
- newly diagnosed
- acute myeloid leukemia
- squamous cell carcinoma
- prognostic factors
- peritoneal dialysis
- radiation therapy
- clinical trial
- cross sectional
- allogeneic hematopoietic stem cell transplantation
- patient reported
- temporal lobe epilepsy